Search the Newsreel

Altisource Portfolio Solutions (NASDAQ:ASPS) Downgraded to "Strong Sell" Rating by Zacks Research

Zacks Research has downgraded Altisource Portfolio Solutions (NASDAQ:ASPS) from a "hold" to a "strong sell" rating, with Weiss Ratings also lowering its rating. Despite this, MarketBeat's consensus remains "hold" with an $8.00 price target. The company reported quarterly EPS of $0.17, missing estimates, while …

Altisource Portfolio Solutions SA (ASPS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Altisource Portfolio Solutions SA (ASPS), focusing on its support and resistance levels, various technical indicators, and moving averages. ASPS currently has a price momentum score of 5.24, trading between a resistance of $6.99 and support of $4.11, …

ALTI|AlTi Global, Inc|Price:3.827|Chg%:+0.227

AlTi Global, Inc. is an independent global wealth manager offering fiduciary capabilities, alternative investment strategies, and advisory services. The company operates through its Wealth & Capital Solutions segment, providing comprehensive wealth management and OCIO services, and an International Real Estate segment focused on co-investments …

Freehold Royalties Announces Second Quarter 2026 Results

Freehold Royalties Ltd. CALGARY, Alberta, July 29, 2026 (GLOBE NEWSWIRE) -- Freehold Royalties Ltd. (Freehold or the Company) (TSX:FRU) announces results for the three months ended June 30, 2026. Second Quarter Highlights Total production of 15,622 boe/d(1) including crude oil and natural gas liquids …

Altisource Portfolio Solutions (NASDAQ:ASPS) CEO Acquires $20,720.00 in Stock

Altisource Portfolio Solutions CEO William Shepro recently purchased 4,000 shares of the company's stock for $20,720, increasing his ownership by over 85%. This insider buying activity occurred despite the company's shares trading near their 52-week low and a recent earnings per share miss, though …

H.C. Wainwright reiterates Altimmune stock rating on trial results

H.C. Wainwright has reiterated a Buy rating and a $20.00 price target for Altimmune (NASDAQ:ALT) following positive Phase 2 trial results for its drug candidate, pemvidutide, in treating alcohol use disorder. The drug met its primary endpoint by significantly reducing heavy drinking days and …

Tomer Energy Royalties (2012) Ltd. Revenue Breakdown – TASE:TOEN

ASPS|Altisource Portfolio Solutions SA|Price:5.000|Chg%:-0.110

Altisource Portfolio Solutions SA (ASPS) shows healthy fundamentals and high growth potential, though its stock price has been weak recently. The company is considered fairly valued within the Real Estate Operations industry, and institutional ownership is very high. Analysts currently rate ASPS as a …

Altisource Portfolio Solutions SA (ASPS) Financial Health: Profitability & Balance Sheet Analysis

Altisource Portfolio Solutions SA (ASPS) has a stable financial status with a current score of 6.70, ranking 26th out of 47 in the Real Estate Operations industry. The company reported significant year-over-year growth in its latest quarterly revenue by 96.27% and net profit by …

Altimmune Inc RECLAIM Phase 2 Trial in AUD Topline Results Conference Call Transcript

This article provides the transcript for Altimmune Inc.'s RECLAIM Phase 2 Trial in AUD Topline Results Conference Call held on July 28, 2026. The call began with an introduction by Louis Sine, Vice President of Investor Relations, and detailed how participants could ask questions. …

New MAC Sales And Revenue Metrics Might Change The Case For Investing In Deterra Royalties (ASX:DRR)

Why Is Ecora Royalties (LSE:ECOR) Drawing Fresh Market Attention?

Boston Pizza Royalties Q2 Results: Aug 13 Earnings Date Set

BOSTON PIZZA ROYALTIES INCOME FUND AND BOSTON PIZZA INTERNATIONAL INC. TO ANNOUNCE 2026 SECOND QUARTER RESULTS ON AUGUST 13TH

Ecora Royalties Delivers Strong Q2 Cash Flow as Critical Minerals Portfolio Drives Growth

Altimmune Scores Alcohol Use Disorder Win As Lilly, Novo Circle Same Indication

Altimmune has achieved a significant milestone in treating alcohol use disorder, a field also being explored by major pharmaceutical companies like Eli Lilly and Novo Nordisk. The article highlights Altimmune's efforts to innovate the treatment paradigm for this condition.

Altimmune’s GLP-1 Drug Reduces Heavy Drinking in Alcohol Use Disorder Trial

Altimmune's experimental GLP-1 drug, pemvidutide, significantly reduced heavy drinking days in a Phase 2 trial for alcohol use disorder. The drug, which targets both GLP-1 and glucagon receptors, also aims to treat the fatty liver disease MASH and showed a robust clinical profile compared …

Altimmune Says Lead Drug Shows Significant Alcohol Reduction in Mid-Stage Study

Altimmune announced positive top-line results from its RECLAIM Phase 2 trial for pemvidutide, showing significant reductions in heavy drinking days and improvements across secondary endpoints for alcohol use disorder. The drug also achieved significant body weight reduction and demonstrated a favorable tolerability profile. Altimmune …

Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial

Altimmune's experimental drug pemvidutide successfully met its primary endpoint in a Phase II trial for alcohol use disorder (AUD), significantly reducing heavy drinking days and improving other key measures. The company plans to seek an FDA end-of-Phase-II meeting to discuss moving towards a Phase …

ALT Stock Holds Range As Traders Weigh Cash And Losses

Altimmune Inc. (ALT) stock is consolidating between $2.75 and $3.05 after recent selling pressure, despite a 12.16% surge driven by clinical trial progress. The company boasts a strong balance sheet with $331.5M in cash, providing a long funding runway, but continues to post significant …

ALT Stock Holds Range As Cash Runway Supports Speculative Trading

Altimmune Inc. (ALT) stock has been trading up by 11.82%, primarily driven by promising clinical trial progress. Despite recent sideways trading between $2.75 and $3.15, the company has a strong balance sheet with $97.6M in cash and minimal debt, providing a significant runway despite …

Altimmune rises as GLP-1 cuts drinking in mid-stage trial

Altimmune (ALT) shares rose over 15% in premarket trading after its GLP-1 candidate, pemvidutide, demonstrated a reduction in drinking in a mid-stage trial for patients with alcohol use disorder. The biotech company, headquartered in Gaithersburg, Maryland, released topline data from the study.

Altimmune reports positive Phase 2 RECLAIM topline results for pemvidutide in AUD

Altimmune announced positive topline Phase 2 results for its drug pemvidutide 2.4 mg in treating Alcohol Use Disorder (AUD), demonstrating a significant reduction in heavy drinking days compared to placebo. The RECLAIM study met its primary endpoint and two FDA-recognized secondary endpoints, showing favorable …

Altimmune stock surges 18% on positive trial results

Altimmune Inc. (NASDAQ:ALT) shares surged 18% after the company announced positive topline results from its RECLAIM Phase 2 trial of pemvidutide for alcohol use disorder. The trial met its primary and key secondary endpoints, showing a statistically significant reduction in heavy drinking days and …

ALT|Altimmune Inc|Price:3.030|Chg%:+0.030

Altimmune Inc Financials

This article provides a detailed financial summary of Altimmune Inc (ALT), including its latest stock price, market capitalization, and key financial indicators. It presents extensive quarterly and annual data for EPS, Revenue, Net Profit, Balance Sheet items, and Cash Flow, based on reports up …

Altimmune Inc (ALT) Balance Sheet

This article provides detailed balance sheet data for Altimmune Inc (ALT), allowing users to evaluate its financial health through quarterly and annual figures. It includes key financial metrics like cash and short-term investments, total assets, liabilities, and shareholders' equity, along with supporting FAQs. The …

Altius Minerals doubles down on TNR Gold's royalty strategy as first cashflow nears

TNR Gold Corp (TSX-V:TNR, FRA:TNW, OTC:TRRXF) executive chairman Kirill Klip joined Proactive's Stephen Gunnion to discuss key milestones across the company's royalty portfolio, from fresh institutional backing to the first signs of cash flow. Altius Minerals has increased its TNR holding to 30,935,000 shares …

Altimmune Market Sentiment

This article provides an overview of the market sentiment for Altimmune (ALT), including analyst consensus, short interest, options flow, and insider activity. It highlights a strong "Buy" consensus from analysts with ambitious price targets and notes a significant short interest of 24.5%. The article …

Versamet Royalties Ord Shs (VMET) Financial Health: Profitability & Balance Sheet Analysis

ASPS|Altisource Portfolio Solutions SA|Price:5.800|

This article provides a detailed company profile of Altisource Portfolio Solutions SA (ASPS), a Luxembourg-based integrated service provider for the real estate and mortgage industries. It covers the company's background, business scope, key financial data including market cap and P/E ratio, and lists its …

Altisource Portfolio Solutions SA (ASPS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Altisource Portfolio Solutions SA (ASPS) has an earnings forecast score of 8.00, placing it 7th in the Real Estate Operations industry. Based on one analyst, the stock is rated as a "Buy" with a target price indicating a 37.93% upside. The expected revenue for …

ETFs Investing in Altimmune, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Altimmune, Inc. (ALT). It provides a detailed table including each ETF's market value, weight of ALT stock, issuer, management style, focus, expense ratio, assets under management (AUM), price, change, relative volume, and …

Altimmune Inc (ALT) Income Statement

This article provides a detailed quarterly and annual income statement for Altimmune Inc (ALT) from 2012 to 2026, offering insights into its financial performance, including total revenue, operating expenses, and net income. It also includes an FAQ section explaining how to interpret the income …

Altisource Portfolio Solutions S.A. - Net Settle Stakeholder Revenue Breakdown – BOATS:ASPSW

Altisource Portfolio Solutions S.A. (BOATS:ASPSW) generated $170.97 million USD in revenue last year. The majority of this revenue, $134.84 million USD, came from its Servicer and Real Estate segment, an increase from $128.95 million USD the previous year. The United States was the company's …

Altimmune, Inc. Revenue Breakdown – NASDAQ:ALT